Contact Us
Drug Search Results
More Filters [+]

Azasetron

Alternative Names: azasetron
Latest Update: 2024-12-14
Latest Update Note: Clinical Trial Update

Product Description

Azasetron (Serotone) is a potent and selective 5-HT3 receptor antagonist, and classified as benzamide derivative. It has a different chemical structure from indole-type 5-HT3 receptor antagonists such as granisetron, ondansetron, ramosetron and tropisetron. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/10396331/)

Mechanisms of Action: 5-HT3 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sensorion
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Azasetron

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ChiCTR2300076786

N/A

Not yet recruiting

Unknown

2024-10-20

ChiCTR2200060139

N/A

Not yet recruiting

Chronic Pain|Pain, Postoperative

2023-12-31

ChiCTR2100049246

N/A

Not yet recruiting

Other

2021-12-31

ChiCTR2000039603

N/A

Recruiting

Unknown

2021-12-01

Recent News Events

Date

Type

Title

02/16/2024

PubMed

 Sub-anesthetic dose of esketamine decreases postoperative opioid self-administration after spine surgery: a retrospective cohort analysis.

01/25/2022

PubMed

 Sustainable and efficient skin absorption behaviour of transdermal drug: The effect of the release kinetics of permeation enhancer.

12/13/2021

PubMed

 Effects of Dexmedetomidine on Postoperative Nausea and Vomiting in Adult Patients Undergoing Ambulatory Thyroidectomy: A Randomized Clinical Trial.

09/11/2019

News Article

 Sensorion Announces Three Presentations at IEB 2019 in Padua

06/28/2019

News Article

 Sensorion Receives European Medicines Agency Agreement on the Pediatric Investigation Plan (PIP) for Arazasetron (SENS-401) in Two Indications

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions